Information Provided By: 
Fly News Breaks for March 21, 2019
AGLE
Mar 21, 2019 | 06:25 EDT
JPMorgan analyst Anupam Rama started Aeglea BioTherapeutics with an Overweight rating and $14 price target. Aeglea is an emerging player in the rare disease space and its lead asset pegzilarginase "has multiple de-risking points" for lead indication arginase 1 deficiency, Rama tells investors in a research note. This is a disease with a clear unmet need for which there are no approved therapies to directly target cause and limited competition, the analyst adds.
News For AGLE From the Last 2 Days
There are no results for your query AGLE
